Synthetic Biologics (NYSEAMERICAN:SYN) was upgraded by Zacks Investment Research from a “hold” rating to a “strong-buy” rating in a research note issued on Thursday. The firm currently has a $0.75 price objective on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 13.64% from the company’s previous close.
According to Zacks, “Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The Company is engaged in developing product candidates to treat pulmonary arterial hypertension, relapses in multiple sclerosis, cognitive dysfunction in multiple sclerosis, fibromyalgia and amyotrophic lateral sclerosis. Synthetic Biologics, Inc., formerly known as Adeona Pharmaceuticals, Inc., is headquartered in Ann Arbor, Michigan. “
Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Synthetic Biologics in a research note on Tuesday, November 20th.
Synthetic Biologics (NYSEAMERICAN:SYN) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.93) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.32) by $0.39.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.
Read More: Book Value Per Share – BVPS
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.